Japan’s Astellas Pharma Inc has agreed to buy Audentes Therapeutics Inc for about $3 billion in cash as it seeks to make genetic medicines a key area of growth.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
